Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $786.4 million.

  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity rose 79.06% to $786.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 90.80%. This contributed to the annual value of $864.6 million for FY2024, which is 149.10% up from last year.
  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity amounted to $786.4 million in Q3 2025, which was down 3.52% from $815.1 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity's 5-year high stood at $864.6 million during Q4 2024, with a 5-year trough of $471,098 in Q2 2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity averaged around $556.3 million, with its median value being $488.5 million (2024).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first dropped by 27.46% in 2023, then soared by 94,718.91% in 2024.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity stood at $478.5 million in 2022, then dropped by 27.46% to $347.1 million in 2023, then soared by 149.10% to $864.6 million in 2024, then spiked by 79.06% to $786.4 million in 2025.
  • Its last three reported values are $786.4 million in Q3 2025, $815.1 million for Q2 2025, and $818.4 million during Q1 2025.